LimmaTech Biologics has entered into a strategic partnership for the development, production and commercialization of the vaccine candidate SV4 against shigellosis, a diarrheal disease caused by Shigella bacteria, with Valneva SE from Saint-Herblain, located on the outskirts of the French city of Nantes. According to a press release, Valneva will receive an exclusive global license for S4V from LimmaTech, while LimmaTech will bank an upfront payment of 10 million euros and will be eligible to receive additional milestone payments and commission in the future.
LimmaTech will be responsible for conducting a Phase 2 Controlled Human Infection Model (CHIM) and a Phase 2 pediatric study. Both clinical trials are scheduled to begin in 2024. Valneva will take on all further development activities, including industrialization, regulatory aspects and, once approval has been secured, worldwide commercialization.
Shigellosis is a serious infection and the second leading cause of fatal diarrheal disease, especially in young children. It is estimated that up to 165 million infections and 600,000 deaths are caused by the Shigella bacteria each year, the press release explains.
Valneva’s proven expertise in late-stage development and commercialization of vaccines “will expedite potential market approval and bring a Shigella vaccine to people in need”, comments Franz-Werner Haas, CEO of LimmaTech Biologics AG, in the press release.
“The Shigella vaccine candidate enables a potential first-in-class vaccine solution for both LMICs and travelers and, as such, represents a potentially highly synergistic product for Valneva”, as Thomas Lingelbach, CEO of Valneva, states in the press release.
LimmaTech Biologics is headquartered in Schlieren in the Swiss canton of Zurich and is a member of Bio-Technopark Schlieren-Zurich. ce/gba
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space